Gan & Lee Pharmaceuticals: Insulin Glargine Injection receives marketing authorization in El Salvador

Gan & Lee Pharmaceuticals announced that the company recently received a registration approval for insulin glargine injection issued by El Salvador's Directorate General of Health Regulation. The drug is a basal long-acting insulin used for the treatment of diabetes in adults, adolescents, and children aged 2 years and older. As of June 30, 2026, the company had invested a cumulative 962 million yuan in research and development expenses for the insulin glargine project. After approval, the product can be sold in El Salvador, but the pace of market expansion and sales scale remain uncertain.